Contact:
4008465777
-
About Us
News & Events
-
12-16
Tonghua Dongbao: URAT1 inhibitor (THDBH130 Tablets) is approved for clinical trial
On December 15, 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") received the notice of approval (No. CXHL2101548 and CXHL2101549) from the Center for Drug Evaluation of the National Medical Products Administration for the clinical trial of its URAT1 inhibitor (THDBH130 Tablets).
-
11-26
Tonghua Dongbao's insulin products win the bid for centralized procurement, increasing the company's market share
On November 26, 2021, China's Joint Procurement Office (JPO) released the preliminary results of the sixth round of volume-based procurement (VBP) tender for insulin. Tonghua Dongbao's insulin products won the bid as Category B candidates, which conforms to the management's expectation and its business plan. Benefiting from the diverse product portfolio and economies of scale, the Company can further increase its market share while earning a steady stream of profits, which lays a solid foundation for its vision of becoming an explorer and leader of novel drug R&D in the field of endocrinology.
-
11-12
Tonghua Dongbao wins Golden Bridge Award for Most Valuable Pharmaceutical Company of the Year
On November 11, 2021, the 2021 Thinking Finance Annual Investors Meeting and Golden Bridge Awards Ceremony was held in Shanghai. Tonghua Dongbao won the Golden Bridge Award for the Most Valuable Pharmaceutical Company of the Year.
-
10-27
Tonghua Dongbao records 41.28% YoY increase in net profit attributable to parent company for first 3Qs
On the evening of October 27, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its quarterly report for Q3 2021. In...
-
10-21
Tonghua Dongbao's Insulin Aspart, as part of basal-bolus therapy, approved for sale in China
Tonghua Dongbao's Insulin Aspart Injection (tradename: Ruisulin) was approved for sale in China the other day, adding another member to the Company's insulin analog family since the launch of ...
-
10-20
Tonghua Dongbao wins 2021 China ESG Award for Best Environment Case
On October 19, 2021, the 2021 CLS ESG Summit Forum was held in Shanghai by Cailianshe (CLS) under the guidance of Shanghai United Media Group. Tonghua Dongbao won the 2021 China ESG Award for Best Env...